REG - NetScientific PLC - PDS Phase 2 Clinical Trial Update

NetscientificAnnouncement

06/12/2021 14:55

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211206:nRSF7206Ua&default-theme=true

RNS Number : 7206U  NetScientific PLC  06 December 2021

NetScientific plc

 

("NetScientific", the "Group" or the "Company")

 

PDS Phase 2 Clinical Trial Update

 
PDS Biotech Provides Recruitment update for National Cancer Institute-Led Phase 2 Clinical Trial of PDS0101-Based Combination

 

London, UK - 06 December 2021 - NetScientific plc (AIM: NSCI), the
international life sciences and sustainability technology investment and
commercialisation Group,  announces that its portfolio company, PDS
Biotechnology Corporation (Nasdaq: PDSB), has announced the reopening of
recruitment in the National Cancer Institute (NCI)-led Phase 2 clinical trial
(NCT04287868) evaluating PDS0101 (Versamune®-HPV16) in combination with two
investigational immune-modulating agents in advanced HPV cancers.

 

The suspension of recruitment was administrative in nature and was unrelated
to any specific safety or efficacy concerns associated with the triple
combination being studied. As a result, during the recruitment suspension,
patients already enrolled in the study continued to receive scheduled
treatment. The timing of clinical results from this trial is not expected to
be affected by the pause in recruitment of new patients.

 

The trial is evaluating the novel triple combination in two groups of
patients. Firstly, in second line treatment of recurrent or metastatic
HPV-positive cancers including anal, cervical, head and neck, penile, vaginal,
and vulvar cancers in patients who are naïve to checkpoint inhibitors and
have not responded to at least one standard of care therapy. Secondly in third
line treatment of the above recurrent or metastatic HPV-positive cancers in
patients who have not responded to at least two standard of care therapies
including checkpoint inhibitor treatment.

 

Dr. Lauren V. Wood, PDS Biotech's Chief Medical Officer commented: "We are
pleased that the NCI, part of the National Institutes of Health, quickly
obtained IRB approval to resume recruitment in this important trial. We
believe the interim data demonstrated that this combination has the potential
to significantly improve clinical outcomes for patients with advanced,
refractory HPV16-positive cancers who have limited treatment options. Our
approach of treating multiple types of cancer based on their molecular
profiles rather than tissue location, may have the potential to provide safe
Versamune®-based treatment options to an expanded population of patients
suffering from multiple types of cancer and at different stages of disease."

 

Ilian Iliev, CEO of NetScientific, commented: "As anticipated in our
announcement dated 21 October 2021, this temporary suspension in the
recruitment for patients for one of the PDS Biotech Phase 2 clinical trials
has now been restarted. The suspension was administrative in nature, unrelated
to any specific safety or efficacy concerns, and has not affected the timing
of expected clinical results from this trial. Alongside this NCI trial, PDS is
continuing to make progress in the other Phase 2 trials and other projects
underway. We look forward to clinical data and the next milestones, and remain
supportive of PDS' management."

 

Full details of the announcement from PDS can be viewed here:
https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/113-2021-news/576-iotechrovidesecruitmentupdateforationalancer20211206
(https://www.pdsbiotech.com/investors/news-center/press-releases/press-releases1/113-2021-news/576-iotechrovidesecruitmentupdateforationalancer20211206)

 

 

For more information, please contact:

 

 NetScientific                                     Via Walbrook PR
 Ilian Iliev, CEO

 WH Ireland (NOMAD, Financial Adviser and Broker)
 Chris Fielding / Darshan Patel                    +44 (0)20 7220 1666

 Walbrook PR
 Nick Rome/ Paul McManus/                          07748 325 236, 07980 541 893

 Nicholas Johnson                                  or 07884 664 686

 

About NetScientific

NetScientific plc (AIM: NSCI) is a holding company, that invests in, develops,
commercialises and realises shareholder value in life sciences/healthcare,
sustainability and technology companies, which offer significant growth
potential predominately in the UK and USA, as well as globally.

 

With the acquisition of EMV Capital in August 2020, the Group doubled its
portfolio from 8 to 17 companies, either through direct subsidiary, balance
sheet investment or capital under advisory, varying from start-up private
companies to publicly listed equities.

 

NetScientific delivers shareholder returns through a proactive and hands-on
management approach to their portfolio companies; identifying, investing in,
and helping to build game-changing companies. The Group targets value
inflection points and the release of value through partial or full exits from
trade sales, public listings, or equity sales. The Company has a strong
transatlantic and growing international presence, providing attractive
expansion prospects.

 

NSCI can deploy a capital-light investment structure; utilising the power of
the PLC Brand, and the NetScientific balance sheet to anchor future
investments and achieve a multiplier effect by attracting 3rd party investment
for the portfolio companies.

 

NetScientific is headquartered in London, United Kingdom, and was admitted to
trading on AIM, a market operated by the London Stock Exchange, in 2013
(website: www.netscientific.net (https://netscientific.net/) ).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDTFBITMTIMBPB